Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study
暂无分享,去创建一个
M. Hochberg | C. Rosen | M. McClung | R. Kagan | D. Thompson | A. D. de Papp | S. Broy | S. Bonnick | R. Petruschke | E. Chen | P. Miller
[1] D. Bauer,et al. Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Ego Seeman,et al. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. , 2004, Bone.
[3] J. Rodriguez-Portales,et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.
[4] J. Reginster,et al. Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] C. Cooper,et al. Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta‐Analyses , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] P. Delmas,et al. Long‐Term Variability of Markers of Bone Turnover in Postmenopausal Women and Implications for Their Clinical Use: The OFELY Study , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] R. Eastell,et al. Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] J. Reginster,et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. , 2003, Maturitas.
[9] R. Eastell,et al. Biochemical Markers of Bone Turnover and Fracture Prediction , 2003, The journal of the British Menopause Society.
[10] J. Reginster,et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study , 2003, Current medical research and opinion.
[11] Jacques P. Brown,et al. The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis , 2002, Calcified Tissue International.
[12] Gordon Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.
[13] G. Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. , 2002, Endocrine reviews.
[14] G. Guyatt,et al. III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis , 2002 .
[15] M. Hochberg,et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.
[16] Fran Harris,et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.
[17] R. Marcus,et al. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. , 2002, Endocrine reviews.
[18] D. Black,et al. Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] Ellen Fineout-Overholt,et al. Users' Guides to the Medical Literature , 2002 .
[20] C. Chesnut,et al. Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] M. Meredith,et al. A method to assess the proportion of treatment effect explained by a surrogate endpoint , 2001, Statistics in medicine.
[22] E. Siris,et al. Importance of precision in bone density measurements. , 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[23] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[24] D. Burr,et al. Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] D. Kiel,et al. Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis , 2000, Aging.
[26] D. Kiel,et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .
[27] D L Sackett,et al. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. , 1999, JAMA.
[28] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[29] G. Guyatt,et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. , 1999, JAMA.
[30] S. Cummings,et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. , 1999, Arthritis and rheumatism.
[31] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[32] Ron Johnston,et al. Review of A Solution to the Ecological Inference Problem: Reconstructing Individual Behaviour from Aggregate Data by King, G , 1998 .
[33] M F Huque,et al. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. , 1997, Statistics in medicine.
[34] C Marcelli,et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] P. Delmas,et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[36] S. Cummings,et al. Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. , 1995, Arthritis and rheumatism.
[37] S. Cummings,et al. Bone density at various sites for prediction of hip fractures , 1993, The Lancet.
[38] H K Genant,et al. Axial and appendicular bone density predict fractures in older women , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] M. Peacock,et al. Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women , 2007, Osteoporosis International.
[40] O. Johnell,et al. Uncertain Future of Trials in Osteoporosis , 2002, Osteoporosis International.
[41] G. Guyatt,et al. Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .
[42] G. Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. , 2002, Endocrine reviews.
[43] C. Christiansen,et al. Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.
[44] P. Miller,et al. Antifracture efficacy of antiresorptive agents are related to changes in bone density. , 2000, The Journal of clinical endocrinology and metabolism.
[45] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[46] D. Hans,et al. Do Markers of Bone Resorption Add to Bone Mineral Density and Ultrasonographic Heel Measurement for the Prediction of Hip Fracture in Elderly Women? The EPIDOS Prospective Study , 1998, Osteoporosis International.
[47] G. Guyatt,et al. Users' guides to the medical literature. , 1993, JAMA.